Susquehanna Fundamental Investments’s Viking Therapeutics VKTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-72,700	Closed	-$460K	–	1789
2021 Q1	$460K	Buy	+72,700	New	+$511K	0.01%	1173
2020 Q4	–	Sell	-20,000	Closed	-$116K	–	1613
2020 Q3	$116K	Sell	20,000 -1,900	-9%	-$13.1K	﹤0.01%	1266
2020 Q2	$158K	Buy	+21,900	New	+$145K	0.01%	863

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna Fundamental Investments's VKTX Position: Q2 2021 in Review

Susquehanna Fundamental Investments sold out of Viking Therapeutics (VKTX) in Q2 2021, closing a stake of 72,700 shares — an estimated $460K sold.

Susquehanna Fundamental Investments first reported a position in VKTX in Q2 2020 and held it in 3 quarters. The position peaked at $460K in Q1 2021. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2021.

Susquehanna Fundamental Investments reported no remaining Viking Therapeutics position as of Q2 2021 after selling out during the quarter.
Susquehanna Fundamental Investments sold 72,700 Viking Therapeutics shares in Q2 2021, an estimated $460K.
Susquehanna Fundamental Investments first reported a position in Viking Therapeutics in Q2 2020 and held it in 3 quarters.
Susquehanna Fundamental Investments's Viking Therapeutics position peaked at $460K in Q1 2021.
138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2021, filed 11 Aug 2021.